• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
BCRX [ BioCryst Pharmaceuticals Inc ]
Last Trade 4.21 Date 8/6/2020
Change % -0.48 % Price Change -0.02
Open 4.23 52 Week High 6.2862
High 4.3172 52 Week Low 1.38
Low 4.09 Type stock
Volume 6105457 Average Volume 3492687
Prev Close 4.23 Stock Exchange NASDAQ
Bid 4.26 Ask 4.29
Bid Size 11 Ask Size 2
1st Yr Estimated EPS Growth -0.1118 2nd Yr Estimated EPS Growth -0.0625
2 Years Forward Earning Yield -0.1773 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.0207 Book Value Yield 0.0049
Buy Back Yield CAPE Ratio
Cash Return -0.103 Cash Flow per Share -0.6783
Cash Flow Yield -0.1603 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.2128 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 19.1216 EV / Pre Tax Income
EV / Revenue 15.0375 EV / Total Asset 5.2593
Expected Dividend Growth Rate Free Cash Flow per Share -0.6812
Free Caash Flow Ratio Free Cash Flow Yield -0.161
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1891 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 204.544028 PB Ratio 10 Year Growth 0.509959
PB Ratio 3 Year Growth 34.882566 Cash Ratio 3 Year Average 579.1833
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.039312
Price to Cash Ratio 6.599945 Price / EBITDA
Price to Sales Ratio 11.209863 Price to Sales Ratio 10 Year Growth 0.15673
Price to Sales Ratio 3 Year Avg 22.222552 Price to Sales Ratio 5 Year Avg
Sale per Share 0.3773 Sales Yield 0.0892
Sustainable Growth Rate -8.8275 Tangible Book Value per Share 0.0207
Tangible Book Value per Share 3 year Avg 0.4723 Tangible Book Value per Share 5 year Avg 0.4688
Total Asset per Share 0.7743 Total Yield
Working Capital per Share 0.186 Working Capital per Share 3 Year Avg 0.5465
Working Capital per Share 5 Year Avg 0.4181 Beta 2.729666
Company Profile

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS). Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX-4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama.